Alcon to Acquire LenSx Lasers, Inc., Developer of Femtosecond Laser Technology for Increased
Precision of Manual Surgical Steps during Cataract Surgery
HUENENBERG, Switzerland – July 6, 2010 – Alcon, Inc. (NYSE: ACL ) announced today that it has
entered into a definitive agreement to acquire LenSx Lasers, Inc, a privately held company that developed the
first femtosecond laser to receive U.S. Food and Drug Administration (FDA) clearance for use as a part of
cataract surgery. The LenSx system is indicated for anterior capsulotomy and laser phacofragmentation during
cataract surgery, providing a complementary surgical approach to certain manual steps within the traditional
Alcon will pay US $361.5 million in cash at closing to LenSx shareholders for their shares, plus maximum
contingent payments of US $382.5 million based upon the achievement and over-achievement of future
femtosecond unit and procedure fee revenue milestones. The closing of this acquisition is subject to receipt of
required regulatory approvals and customary closing conditions.
The innovative LenSx laser platform enables surgeons to perform some of the most delicate manual steps
of cataract surgery with image-guided visualization and micron level laser precision. The LenSx laser enhances a
surgeon’s ability to predictably create a well centered anterior capsulorhexis of exact diameter, and to effectively
fragment the lens for removal with minimized phaco time and power.
“This complementary technology aligns with Alcon’s strategic focus to help surgeons improve every step
of the cataract procedure. The LenSx laser provides surgeons a new level of predictability and control over
critical manual steps during cataract removal – making those steps more precise and reliable,” said Stuart
Raetzman, vice president, Global Marketing and area president for the United States.
“The LenSx femtosecond laser has been designed to advance the precision and reproducibility of key